Treatment of Metastatic Renal Cell Carcinoma With Autologous T-Lymphocytes Genetically Retargeted Against Carbonic Anhydrase IX: First Clinical Experience

Weijtens MEM, Willemsen RA, Valerio D, et al: Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J Immunol 157:836,1996-843,

10.1038/sj.cgt.7700477

Lamers CHJ, Willemsen RA, van Elzakker P, et al: Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: Implications for clinical immunogene therapy of cancer. Cancer Gene Ther 10.1038/sj.cgt.7700916 (Epub ahead of print on November 11, 2005)

10.1089/hum.2005.16.1452

Divgi CR, O'Donoghue JA, Welt S, et al: Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med 45:1412,2004-1421,

10.1200/JCO.2005.07.732

10.1073/pnas.0405730101

10.1200/JCO.2005.00.240

10.1038/sj.bjc.6601617

Steffens MG, Boerman OC, Oyen WJ, et al: Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: Implications for fractionated dose radioimmunotherapy. Cancer Res 59:1615,1999-1619,

Steffens MG, Oosterwijk-Wakka JC, Zegwaart-Hagemeier NE, et al: Immunohistochemical analysis of tumor antigen saturation following injection of monoclonal antibody G250. Anticancer Res 19:1197,1999-1200,